$0.1600
-0.02-11.16%
al cierre: -
$0.1664
0.006404.00%
After hour: 7:59 PM EDT
Comments
Loading...
Estimaciones de beneficios, BPA e ingresos
Adaptimmune Therapeutics informa las ganancias trimestralmente. Estos informes de ganancias trimestrales ofrecen a los inversores una visión de los resultados financieros de una empresa durante un período de 3 meses. Los informes de ganancias casi siempre incluyen resultados de EPS e ingresos.
Fecha de beneficios
nov 12
Estimación de BPA
$-0.110
Estimación de ingresos trimestrales
$11.26M
Ingresos anuales
(a partir de jun 30)
(a partir de jun 30)
$65.08M
Analice el historial de beneficios de Adaptimmune Therapeutics utilizando filtros y clasificaciones avanzadas.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
ADAP | Adaptimmune Therapeutics | -$0.07 | -$0.11 | — | — | $40.90M | $11.26M | — | — | 11/12/2025 | |
ADAP | Adaptimmune Therapeutics | $0.04 | -$0.14 | -$0.02 | 85.71% | $128.23M | $7.94M | $13.68M | 72.22% | 08/13/2025 | |
ADAP | Adaptimmune Therapeutics | -$0.03 | -$0.17 | -$0.03 | 82.35% | $5.68M | $6.55M | $7.29M | 11.22% | 05/13/2025 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.15 | -$0.30 | -100.00% | $231.00K | $8.42M | $3.22M | -61.73% | 03/20/2025 | |
ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.13 | -$0.07 | 46.15% | $7.32M | $11.17M | $40.90M | 266.17% | 11/13/2024 | |
ADAP | Adaptimmune Therapeutics | -$0.12 | -$0.08 | $0.24 | 400.00% | $5.13M | $38.48M | $128.23M | 233.24% | 08/12/2024 | |
ADAP | Adaptimmune Therapeutics | $0.00 | -$0.10 | -$0.18 | -80.00% | $47.60M | $10.73M | $5.68M | -47.08% | 05/15/2024 | |
ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.10 | -$0.24 | -140.00% | $11.03M | $20.47M | $231.00K | -98.87% | 03/06/2024 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.15 | -$0.18 | -20.00% | $7.01M | $10.28M | $7.32M | -28.80% | 11/08/2023 | |
ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.13 | -$0.12 | 7.69% | $5.54M | $8.78M | $5.13M | -41.57% | 08/09/2023 | |
ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.14 | $0.00 | 100.00% | $3.58M | $4.93M | $47.60M | 865.54% | 05/12/2023 | |
ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.18 | 28.00% | $1.42M | $4.12M | $11.03M | 167.67% | 03/06/2023 | |
ADAP | Adaptimmune Therapeutics | -$0.30 | -$0.24 | -$0.24 | 0.00% | $1.20M | $4.04M | $7.01M | 73.44% | 11/08/2022 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.25 | -$0.28 | -12.00% | $3.10M | $6.00M | $5.54M | -7.70% | 08/04/2022 | |
ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.22 | -$0.32 | -45.45% | $434.00K | $3.29M | $3.58M | 8.66% | 05/09/2022 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | $0.14 | -$0.25 | -278.57% | $1.50M | $96.45M | $1.42M | -98.53% | 03/14/2022 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.26 | -$0.30 | -15.38% | $1.19M | $1.37M | $1.20M | -12.19% | 11/04/2021 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.24 | -$0.24 | 0.00% | $502.00K | $1.36M | $3.10M | 127.57% | 08/09/2021 | |
ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.24 | 4.00% | $761.00K | $1.83M | $434.00K | -76.28% | 05/06/2021 | |
ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.23 | -$0.24 | -4.35% | $728.00K | $1.98M | $1.50M | -24.14% | 02/25/2021 | |
ADAP | Adaptimmune Therapeutics | -$0.06 | -$0.25 | -$0.24 | 4.00% | $237.00K | $870.00K | $1.19M | 37.13% | 11/05/2020 |
Adaptimmune Therapeutics (ADAP) Ganancias por acción
Monto sorpresa de ganancias trimestrales
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | 2025-08-13 | $-0.02 | $-0.14 | 85.7 % |
| Q1 | 2025-05-13 | $-0.03 | $-0.17 | 82.3 % |
| Q4 | 2025-03-20 | $-0.30 | $-0.15 | -100.0 % |
| Q3 | 2024-11-13 | $-0.07 | $-0.13 | 46.2 % |
Adaptimmune Therapeutics (ADAP) Ingresos
Monto sorpresa de ingresos trimestrales
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | 2025-08-13 | $13.68M | $7.94M | 72.2 % |
| Q1 | 2025-05-13 | $7.29M | $6.55M | 11.2 % |
| Q4 | 2025-03-20 | $3.22M | $8.42M | -61.7 % |
| Q3 | 2024-11-13 | $40.90M | $11.17M | 266.2 % |
PREGUNTAS FRECUENTES
¿Cuándo Adaptimmune Therapeutics (NASDAQ:ADAP) publicará los resultados?
Está previsto que Adaptimmune Therapeutics (ADAP) presente resultados el noviembre 12, 2025. Los últimos resultados se publicaron el agosto 13, 2025 para el Q2.
¿Cuáles han sido los últimos beneficios por acción (BPA) de Adaptimmune Therapeutics (NASDAQ:ADAP)?
El BPA real fue de $-0.02, que superó la estimación de $-0.14.
¿Cuáles fueron los ingresos de Adaptimmune Therapeutics (NASDAQ:ADAP)?
Los ingresos reales fueron $13.7M, que superó la estimación de $7.9M.
Explora Estimaciones de beneficios, BPA e ingresos sobre todos los valores.